Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer
The DOI matches its Crossref record.
Abstract
564 Background: Temsirolimus (tem, CCI-779), a novel mTOR inhibitor, is well tolerated and has antitumor activity in heavily pretreated patients (pts) with metastatic breast cancer (MBC, Proc ASCO 22:193,2003). In this trial, we evaluate safety and activity of oral tem in combination with letrozole. Methods: Patients with measurable MBC were randomized in a 1:1:1 ratio (∼30 evaluable pts/arm): 1) letrozole alone or letrozole with 2) tem daily (tem daily arm) or 3) tem daily for 5 days every 2 weeks (tem intermittent arm). All pts received 2.5 mg letrozole daily. Results: Initially, tem doses were 25 mg daily and 75 mg intermittent but were amended to 10 mg daily and 30 mg intermittent because 10 of 12 pts had dose delays, reductions, or discontinuations. Data collected by 15 Nov 2004 are presented for the 92 pts enrolled after the amendment (tem daily: 33; tem intermittent: 30; letrozole alone: 29). Grade 1–4 toxicities, regardless of causality, that occurred in >30% of pts included 10 mg daily: asthenia (45%), mucositis (42%), peripheral edema (36%); 30 mg intermittent: asthenia (63%), mucositis (57%), arthralgia (37%), anorexia (37%), diarrhea (33%), epistaxis (33%); letrozole alone: asthenia (52%), nausea (31%). Grade 3–4 toxicities, regardless of causality, that occurred in >5% of pts included 10 mg daily: hyperglycemia (9%); 30 mg intermittent: hyperglycemia (17%), asthenia (7%), hypertension (7%), hypokalemia (7%); letrozole alone: none. Objective responses (RECIST) occurred, 10 mg daily: 9 PR; 30 mg intermittent: 1 CR, 8 PR; letrozole alone: 2 CR, 10 PR. Clinical benefit (CR + PR + SD ≥8 wks) was 82%, 83%, and 79%, respectively. Progressive disease occurred at ≤8 wks in 12%, 10%, and 14% of pts, respectively. Progression-free survival (PFS) at 1 yr was estimated to be 69%, 62%, and 48%, respectively. Median PFS has been reached for the letrozole alone arm (9.2 mo) but not for the combination arms. Conclusions: Letrozole with 10 mg daily or 30 mg intermittent temsirolimus showed tolerability and clinical activity. Early data suggest that PFS may be longer for the combination arms than for the letrozole alone arm. An actively recruiting phase 3 study is being conducted. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Wyeth Wyeth Wyeth
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Sunitinib: From Rational Design to Clinical Efficacy
Chow, L. Q. M., & Eckhardt, S. G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.3602 · Cited by 883
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
Al-Batran, S.-E., Hartmann, J. T., Probst, S., Schmalenberg, H., Hollerbach, S., Hofheinz, R., Rethwisch, V., Seipelt, G., Homann, N., Wilhelm, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.9378 · Cited by 782
Kumar, B., Cordell, K. G., Lee, J. S., Worden, F. P., Prince, M. E., Tran, H. H., Wolf, G. T., Urba, S. G., Chepeha, D. B., Teknos, T. N., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7662 · Cited by 612
Vokes, E. E., Herndon, J. E., Kelley, M. J., Cicchetti, M. G., Ramnath, N., Neill, H., Atkins, J. N., Watson, D. M., Akerley, W., & Green, M. R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.3569 · Cited by 478
Metadata
- Authors
- Carpenter, J. T., Roché, H., Campone, M., Colomer, R., Jagiello-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J., & Baselga, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-06
- Volume
- 23
- Issue
- 16_suppl
- Pages
- 564-564
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2243880667
- Cited by
- 98
- References
- 0
- Type
- conference abstract
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. https://app.cochat.ai/papers/10.1200/jco.2005.23.16_suppl.564
- The paper
- Carpenter, J. T., Roché, H., Campone, M., Colomer, R., Jagiello-Gruszfeld, A., Moore, L., D’Amore, M., Kong, S., Boni, J., & Baselga, J. (2005). Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.23.16_suppl.564
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.